On behalf of the Society, I am pleased to announce that registration is now open for the CSRC/HESI/FDA/SPS CIPA Update Workshop on December 11, 2014. This is a follow-up meeting to the July 2013 workshop on Rechanneling the Current Cardiac Paradigm.
The workshop will be held at the Double Tree hotel in Silver Spring, Maryland. Please visit the workshop website for details including the registration link and agenda. Additional information about the hotel room block and agenda will be posted on that site in the coming weeks.
SPS members receive discounted registration and should register as “Commercial Industry Members.”
The objective of the CIPA initiative is to engineer an assay platform for assessment of the proarrhythmic potential of new drugs that has improved specificity compared with the hERG assay plus Thorough QT study. Following the July workshop, HESI, CSRC, FDA, SPS and other partners initiated work streams to move the Comprehensive In Vitro Proarrhythmia Assay (CIPA) forward, including: Clinical Translation, Ion Channel, In Silico and Myocyte. SPS has created an Ion Channel Working Group to tackle this initiative, and we will be providing updates on their work to the membership soon.
The December update workshop will bring together global regulators, academicians, drug developers and CRO scientists and will focus on providing information on the latest project developments. We anticipate there to be a high level of participant interaction.
We hope you will consider registering to attend!